Skip to main content
CRVS
NASDAQ Life Sciences

Corvus Q3 2026: $202.9M Cash Funds Operations Into Q2 2028 as Soquelitinib Trials Advance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$9.8
Mkt Cap
$818.497M
52W Low
$6.39
52W High
$26.95
52W Position info
53% above low
Off High info
64% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CRVS sits 53% above its 52-week low of $6.39.

Summary

Corvus reported Q3 2026 results with $202.9 million in cash and securities funding operations into Q2 2028, while R&D spending nearly doubled year over year and the net loss widened to $20.3 million. All major soquelitinib data readouts sit in 2027.


Key Events · Earnings and Guidance · CRVS

  • Q3 2026 Results Reported

    Net loss of $20.3 million for the three months ended September 30, 2026, versus $10.2 million a year earlier, on total operating expenses of $21.4 million.

  • Cash Runway Extended to Q2 2028

    Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, up from $56.8 million at December 31, 2025, including about $189.4 million in net proceeds from the January 23, 2026 financing.

  • R&D Spend Nearly Doubles

    Research and development expense rose $9.3 million to $17.8 million from $8.5 million, driven by higher soquelitinib clinical trial and personnel costs.

  • Data Readouts Clustered in 2027

    Angel Pharma's atopic dermatitis cohort 1 topline is anticipated in March 2027, hidradenitis suppurativa initial data in 1H 2027, and a Phase 2 asthma trial is planned to start by Q1 2027; the Phase 3 PTCL trial continues enrolling toward 150 patients.


Analysis · CRVS · Life Sciences

Corvus ended September 30, 2026 with $202.9 million in cash and securities, up from $56.8 million at year-end 2025 largely on the $189.4 million net proceeds from the January 2026 financing, and says that funds operations into the second quarter of 2028. That removes any near-term financing need, which matters because spending is climbing fast: R&D rose to $17.8 million in the quarter from $8.5 million a year earlier and the net loss widened to $20.3 million from $10.2 million. The pipeline readouts that justify the spend are all in 2027 — Angel Pharma's atopic dermatitis cohort 1 data in March 2027, hidradenitis suppurativa initial data in the first half of 2027, and an asthma Phase 2 trial starting by Q1 2027 — so the stock has a long stretch with no binary data event. The registrational Phase 3 PTCL trial continues enrolling toward 150 patients.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRVS was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $818.5M. The 52-week trading range was $6.39 to $26.95. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRVS - Latest Insights

CRVS
Sep 30, 2026, 6:31 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $11.71
Real-time Price: $9.67 info
Change: -$2.04 (-17%) info
Market Cap: $815.695M info
CRVS
Jun 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.36
Real-time Price: $9.67 info
Change: -$1.69 (-15%) info
Market Cap: $815.695M info
CRVS
May 14, 2026, 7:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $16.25
Real-time Price: $9.67 info
Change: -$6.58 (-40%) info
Market Cap: $815.695M info
CRVS
May 14, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.12
Real-time Price: $9.67 info
Change: -$6.45 (-40%) info
Market Cap: $815.695M info
CRVS
May 07, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $15.02
Real-time Price: $9.67 info
Change: -$5.35 (-36%) info
Market Cap: $815.695M info